Genescience Pharmaceuticals Co. Ltd. has described fused ring kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.
Oncopia Therapeutics Inc. (dba Proteovant Therapeutics Inc.) has divulged protein cereblon (CRBN) ligands and its PROTACs reported to be useful for the treatment of cancer.
Researchers at CNCCS Scarl (Collezione Nazionale Dei Composti Chimici E Centro Screening) and IRBM SpA have disclosed tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP2) inhibitors reported to be useful for the treatment of cancer, Noonan and Leopard syndrome.
Researchers from the U.K. reported seeking protection for a device and method that combines electromyography (EMG) and Raman spectroscopy to improve the diagnostic pathway for patients with neuromuscular disorders, and that may be used as a minimally invasive bedside test of muscle health.
New York University has described protein spinster homolog 2 (SPNS2) inhibitors reported to be useful for the treatment of acute lung injury, autoimmune disease, colitis, Alzheimer’s disease, fibrosis, inflammatory bowel disease, multiple sclerosis and rheumatoid arthritis.
Shenzhen Zhongge Biotechnology Co. Ltd. has synthesized tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or PTPN2 (TCPTP) inhibitors reported to be useful for the treatment of cancer, obesity, atherosclerosis, type 1 diabetes, type 2 diabetes, neurodegeneration, metabolic syndrome and inflammatory bowel disease, among others.
RSS
